(Q54105202)

24 May 2018

title

In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. (English)

1 reference

24 May 2018

1 reference

Aspergillus

1 reference

Abraham OC

1

1 reference

24 May 2018

Manavathu EK

series ordinal

2

1 reference

24 May 2018

Cutright JL

series ordinal

3

1 reference

24 May 2018

Chandrasekar PH

series ordinal

4

1 reference

24 May 2018

publication date

1 January 1999

1 reference

24 May 2018

Diagnostic Microbiology and Infectious Disease

published in

1 reference

24 May 2018

volume

33

1 reference

24 May 2018

issue

1

1 reference

24 May 2018

page(s)

7-11

1 reference

24 May 2018

In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

Therapeutic outcome in invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

In vitro activity of voriconazole against Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

In vitro evaluation of voriconazole against some clinically important fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900102-3

7 January 2021

10.1016/S0732-8893(98)00102-3

Identifiers

DOI

1 reference

24 May 2018

PubMed ID

9990469

1 reference

24 May 2018